|
(Former) HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Opioids and Controlled Substances
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
NIDA
|
The National Institute of Drug Abuse (NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing prescription drug abuse.
|
|
12th Annual Conference on the Science of Dissemination and Implementation
|
Meeting/ Workshop
|
AHRQ
|
NHLBI, NCCIH, NCI, NIAAA, NIAID, NIDA, NIDDK, NIMH, NINR
|
A forum for discussing the science of dissemination and implementation, the 10th annual conference aimed to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine.
|
|
2019 Joint Chinese Academy of Medical Sciences (CAMS)-National Instituties of Health (NIH) Symposium: Research to Support Acceleration towards STOP Tuberculosis (TB)
|
Meeting/ Workshop
|
CDC
|
NIAID
|
The 2019 annual joint meeting of the Chinese Academy of Medical Sciences and the National Institutes of Health focused on tuberculosis, an old infectious disease but still on the top 10 causes of death and the leading cause from a single infectious agent. The meeting provided the opportunity for the researchers from the United States and China to meet and foster possible collaborations and expand our TB collaborations in China.
|
|
A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and renal cell carcinoma
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of renal cell carcinoma (RCC) in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
|
A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating on a cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure.
|
|
A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
CC
|
The National Institutes of Health (NIH) Clinical Center is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management.
|
|
A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial
|
Research Initiative
|
CDC
|
NIAID
|
The purpose of this research initiative is to provide scientific discovery to improve patient care and safety by reducing the duration of treatment for drug-susceptible pulmonary tuberculosis to 4 months by using newregimens, including high-dose rifapentine.
|
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT)
|
Research Initiative
|
FDA
|
NIDA
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) is part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). The mission of the (ACTTION) is to identify, prioritize, sponsor, coordinate, and promote innovative activities with a special interest in optimizing clinical trials that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health.
|
|
Accelerating Medicines Partnership
|
Other
|
FDA
|
OD/OSP, NIA, NIAMS, NIDDK, NINDS
|
Public-private partnership between the National Institutes of Health (NIH), the Food and Drug Administration (FDA), 12 biopharmaceutical companies and multiple non-profit organizations, and managed by the Foundation for NIH (FNIH), to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics.
|
|
AccessGUDID
|
Resource Development
|
FDA
|
NLM
|
The Global Unique Device Identification Database (GUDID) contains key device identification information submitted to the Food and Drug Administration (FDA) about medical devices that have Unique Device Identifiers (UDI). The National Library of Medicine (NLM), in collaboration with the FDA, has created the AccessGUDID portal to make device identification information in the GUDID available for everyone, including patients, caregivers, healthcare providers, hospitals, and industry.
|